Illicit vials and injections marketed as the experimental weight‑loss drug retatrutide are circulating widely in the UK, being offered in gyms, beauty salons, hairdressers and via social media, according to reporting by the BBC. The drug, developed by Eli Lilly, has shown promise in clinical trials but remains unapproved for human use by any regulator.
Open market for an unlicensed product
Pharmacies, regulators and clinical experts are alarmed by the scale and normalisation of sales of what users call "reta", where people are obtaining and self‑administering injections with no reliable information on composition, provenance or safety. The phenomenon is notable because copycat or counterfeit versions of an experimental drug — still in late‑stage testing — are rarely seen at this scale.
"The world has gone mad,"
said Sehar Shahid, pharmacist and director of 24 HR Pharmacy, reflecting concerns that people are injecting an illegal drug while assuming it is safe.
Why experts warn of risk
Retatrutide is currently under clinical evaluation. The BBC notes that even at the Phase III stage of development, only around 50% of drugs in the United States proceed to approval by the Food and Drug Administration. That statistic is often cited by researchers to underline that outcomes from early or mid‑stage trials do not guarantee a product will be licensed or free from previously unobserved harms when tested in larger, more diverse populations.
Public health concerns with counterfeit medicines are twofold: first, a counterfeit product may contain harmful substances or incorrect dosages; second, people using unverified injections for weight loss may delay or eschew other medical evaluation and support. The current situation is compounded by social media posts showing alleged before‑and‑after results and by sellers offering the product through informal, unregulated channels.
- Illicit supply points reported include gyms, nail and beauty salons, hairdressers, social media and even street vendors such as flower sellers.
- Users posting on social platforms claim appetite suppression and rapid weight loss, but there is no independent verification of these reports.
- Real retatrutide remains a trial drug; full safety and efficacy will only be established if and when regulators complete their assessments.
Regulatory and clinical implications
Regulators in the UK and internationally are facing a difficult problem: policing a black market for a product that does not legally exist for patient use. The existence of counterfeit versions of an experimental therapeutic raises questions about supply‑chain security, enforcement priorities and the ability of regulators to protect the public from unlicensed biologics and peptides sold outside clinical settings.
Clinicians and pharmacists have cautioned that preparations sold outside regulated manufacturing and storage conditions may be contaminated, incorrectly labelled or of inconsistent potency. There is also the risk of adverse reactions that are not accounted for in self‑reported testimonials.
| Item | Status / Note |
|---|---|
| Retatrutide regulatory approval | Not approved for human use by any regulatory body |
| Phase III drug approval rate (US reference) | ~50% of drugs at Phase III proceed to approval |
| Reported sale venues | Gyms, salons, hairdressers, social media, street vendors |
Health services encountering patients who have used unregulated weight‑loss injections should treat them as potential adverse drug events and report them through the usual pharmacovigilance systems. Public‑facing harm‑reduction advice is also likely to be required while enforcement and regulatory action are pursued.
Finally, the episode illustrates a recurring tension in modern medicine: high public demand for rapid solutions can outpace regulatory processes and create fertile ground for criminal supply chains that exploit hope, often at considerable personal risk. For now, the only assurance of safety and efficacy for retatrutide will come from completed, regulator‑reviewed trials and the formal licensing process.
